Richard Proehl becomes vp of manufacturing at CML

Has spent more than 30 years in API manufacturing

Cambridge Major Laboratories (CML), a US producer of pharmaceutical intermediates and APIs, has welcomed Richard Proehl as vice president of manufacturing.

Proehl will be responsible for all plant scale manufacturing operations within the organisation, as well as all engineering and EHS functions. He brings more than 30 years of API manufacturing experience to the firm, based in Germantown, WI and has a strong focus on EHS and Quality Compliance.

‘Rick brings a wealth of experience to our team and his focus on quality and execution is a great fit with our company values,’ said Brian Scanlan, president and ceo of CML.

Prior to joining CML, Proehl was the St Louis site director for Covidien, where he was responsible for the company's largest API plant of about 900 employees.

‘The company's growth has been impressive and I will drive operational discipline in our manufacturing systems as we build on our strong fundamental capabilities and provide our customers with world class API manufacturing operations,’ said Proehl.

You may also like

Manufacturing

Cambridge Major Labs supports Summit antibiotic project

The chemistry outsourcing partner will help develop Summit’s antibiotic for Clostridium difficile
Manufacturing

API launch from new Cambridge Major Laboratories facility

This is the first commercial launch of an active pharmaceutical ingredient from its newest facility
Ingredients

AAIPharma Charleston sterile manufacturing receives MHRA approval

<p>International pharmaceutical services provider AAIPharma's sterile manufacturing plant in Charleston, South Carolina, US, has received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) to produce aseptic and lyophilised products.</p>
You need to be a subscriber to read this article.
Click here to find out more.
Manufacturing

Rice-ing to the occasion: how plant-based excipients are gaining ground in pharmaceutical manufacturing

As clean-label expectations migrate from health foods into pharmaceutical supply chains, natural ingredient supplier RIBUS says that rice-based excipients are becoming a credible alternative to synthetic standards
Ingredients

The impact of Brexit on raw materials testing for the pharmaceutical industry (2026 update)

Since the UK departed from the EU, the pharmaceutical regulatory landscape has undergone significant and lasting change; whereas early uncertainty has largely subsided, the system has evolved into a stable but more complex dual framework
Manufacturing

Cipla receives FDA approval for first AB-rated generic of Ventolin HFA in $1.5bn US albuterol market

Indian pharmaceutical company Cipla has secured final FDA approval for its Albuterol Sulfate Inhalation Aerosol, becoming the first AB-rated generic therapeutic equivalent of GlaxoSmithKline's Ventolin HFA
Ingredients

Pangea Pharmaceuticals launches FDA-approved amlodipine oral solution Sdamlo

Pangea’s Sdamlo, the first FDA-approved amlodipine powder for oral solution, leverages a patent-pending lyophilisation process to enable precise unit-dose delivery and improved administration for paediatric, geriatric and dysphagic patients
Subscribe now